Someone asks whether there is anything besides a stimulant.
Sometimes the reason is medical. They have a cardiac history, or blood pressure that is already difficult to control. Sometimes it is a history of substance use they do not want to test. Sometimes they tried a stimulant and the side effects were not tolerable: appetite gone, sleep wrecked, anxiety worse, a rebound crash every afternoon. Sometimes they simply do not want to take a controlled substance, and they are allowed to feel that way without having to justify it.
Whatever the reason, the answer is yes. Non-stimulants are real treatments with real evidence, not a consolation prize handed out when the good option is off the table. But they behave differently enough that going in with stimulant expectations is a reliable way to conclude they failed.
What the Evidence Actually Supports
Two recent analyses are worth knowing about.
A 2018 network meta-analysis in The Lancet Psychiatry pooled 133 double-blind randomized trials across children, adolescents, and adults.1 In adults, amphetamines, methylphenidate, bupropion, and atomoxetine all outperformed placebo. In head-to-head comparisons, amphetamines came out ahead of modafinil, atomoxetine, and methylphenidate on clinician ratings.
A 2025 component network meta-analysis in the same journal looked specifically at adults, pooling 113 randomized trials and comparing pharmacological, psychological, and neurostimulatory approaches.2 Stimulants and atomoxetine were the only interventions with evidence of benefit on core ADHD symptoms in the short term, and notably that held on both self-reported and clinician-reported ratings, which is a harder bar than it sounds.
That second study also delivered two findings that get quoted less often. Atomoxetine was less acceptable than placebo, with an odds ratio of 1.43 for dropping out. And ADHD medications did not show benefit on quality of life measures, with longer-term evidence described as underinvestigated across the board.
So the honest summary is that stimulants generally outperform non-stimulants on core symptoms, non-stimulants clear placebo, and the long-term picture for everything is thinner than anyone would like.
Atomoxetine
A norepinephrine reuptake inhibitor, and the non-stimulant with the strongest adult evidence base.
It is taken daily and works continuously rather than by dose window, so there is no on and off period and no afternoon crash. That is a genuine advantage for people whose demands do not end at 5 p.m.
The tradeoff is onset. Atomoxetine takes several weeks to show its full effect, and the first two weeks are often when side effects are most noticeable and benefit is least noticeable. That combination is exactly what makes people quit early, which is likely part of what the acceptability finding above is measuring. Nausea, appetite reduction, fatigue, and sexual side effects are the common complaints.
It also raises blood pressure and heart rate, which surprises people who assume non-stimulant means cardiovascularly neutral. It is not.
Viloxazine
Also a norepinephrine reuptake inhibitor, FDA approved more recently, with adult approval as well as pediatric.
The practical case for viloxazine is that it is a genuine second option in the same mechanistic family. Someone who did not tolerate atomoxetine has not necessarily exhausted that pathway. Its evidence base in adults is smaller than atomoxetine's simply because it is newer, and it has meaningful drug interactions worth reviewing against a full medication list.
Guanfacine and Clonidine
Alpha-2A adrenergic agonists, which work by a different mechanism entirely: strengthening prefrontal network signaling rather than acting on dopamine or norepinephrine reuptake.
These are FDA approved for ADHD in children and adolescents and used off-label in adults. The adult evidence is thinner than for atomoxetine, though a phase 3 randomized double-blind placebo-controlled trial of extended-release guanfacine in adults did show significant symptom improvement against placebo.4 Worth noting that trial was conducted in Japan, which is a reasonable question to raise about generalizability.
One practical distinction matters here. In a 2025 Lancet Psychiatry cardiovascular analysis, guanfacine was the one ADHD medication that lowered blood pressure and heart rate rather than raising them.3 That can be an advantage in someone with hypertension and a problem in someone who already runs low. Sedation is the most common reason people stop.
Bupropion
Not FDA approved for ADHD, but it beat placebo in adults in the 2018 network meta-analysis, and it is used off-label with reasonable justification.
It is most worth considering when depression is present alongside ADHD, since one medication addressing both is a real advantage. Depression and anxiety are among the conditions we treat alongside ADHD, and treating one without accounting for the other rarely works well. Bupropion lowers the seizure threshold, which rules it out for some patients, and it is generally activating, which some people find helpful and others find intolerable.
What To Expect Going In
The single most useful thing I can set up in advance is the timeline.
Stimulants tell you something on day one. Non-stimulants do not. Atomoxetine may take four to six weeks for a fair assessment, and judging it at week two is judging it during the worst part. People who understand that at the start stay on long enough to find out whether it works. People who do not tend to conclude by day ten that nothing is happening.
The second thing is the shape of the benefit. Stimulants often produce a noticeable window of sharpened focus. Non-stimulants more often produce a flatter, steadier reduction in background noise that people notice retrospectively, when they realize a week went better than usual. Both are real. They do not feel the same, and someone expecting the first will often miss the second.
This is also worth separating from a different situation: a medication that worked for months and then seemed to stop. That has its own list of causes, and the answer there is usually not a switch to a non-stimulant.
A Note on Access
Federal rules governing telehealth prescribing of controlled substances have been in flux for several years, and the current flexibilities have a defined expiration. If you are wondering how ADHD diagnosis and prescribing by video works under current rules, that is covered separately.
Regardless of where the regulations land, having a working knowledge of the non-stimulant options is not a contingency plan. It is part of competent ADHD care, and it was before the regulatory question existed.
If You Are Considering This
If stimulants are not workable for you, for whatever reason, that does not mean your ADHD is untreatable. It means the trial process is slower and requires more patience on both sides.
What it should not mean is being handed one non-stimulant, told to see how it goes, and never followed up. These medications need dose optimization and an honest reassessment at a point where the answer is actually knowable. That is a scheduling and follow-through problem more than a pharmacological one, and it is worth asking a prospective prescriber how they handle it. Our structured evaluation and trial process is built around exactly that problem.
References
1. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727 to 738.
2. Ostinelli EG, Schulze M, Zangani C, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. 2025;12(1):32 to 43.
3. Farhat LC, Lannes A, Del Giovane C, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2025;12(5):355 to 365.
4. Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H. Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry. 2020;81(3):19m12979.
Clarity ADHD is a telehealth psychiatry practice in Washington State offering adult ADHD evaluation and medication management, including care for co-occurring depression and anxiety. Now accepting new patients, and you can start with a free 15-minute consultation to see if it is a fit.
Book a Free 15-Minute ConsultationThe content on this website is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.